Scotiabank Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Stock analysts at Scotiabank initiated coverage on shares of Keros Therapeutics (NASDAQ:KROS - Get Free Report) in a research report issued on Wednesday, MarketBeat.com reports. The firm set a "sector outperform" rating and a $77.00 price target on the stock. Scotiabank's target price suggests a potential upside of 23.83% from the company's current price.

A number of other equities analysts have also recently weighed in on KROS. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Guggenheim assumed coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a "buy" rating and a $96.00 target price for the company. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating on the stock in a research note on Thursday, September 12th. Truist Financial restated a "buy" rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Oppenheimer assumed coverage on shares of Keros Therapeutics in a report on Tuesday, June 25th. They set an "outperform" rating and a $102.00 target price for the company. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $89.11.

Keros Therapeutics Trading Up 3.0 %

KROS stock traded up $1.79 on Wednesday, hitting $62.18. The company's stock had a trading volume of 584,100 shares, compared to its average volume of 372,704. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -11.73 and a beta of 1.23. Keros Therapeutics has a 1 year low of $27.02 and a 1 year high of $73.00. The firm has a 50 day moving average of $52.45 and a two-hundred day moving average of $52.01.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The firm had revenue of $0.04 million during the quarter. During the same period in the previous year, the business earned ($1.27) EPS. As a group, equities analysts forecast that Keros Therapeutics will post -4.88 EPS for the current fiscal year.

Insider Transactions at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the company's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the transaction, the director now owns 119,522 shares of the company's stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 22.90% of the company's stock.

Hedge Funds Weigh In On Keros Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company's stock valued at $870,000 after acquiring an additional 251 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company's stock worth $169,000 after purchasing an additional 324 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Keros Therapeutics by 8.8% in the 1st quarter. Principal Financial Group Inc. now owns 7,063 shares of the company's stock valued at $468,000 after purchasing an additional 574 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company's stock valued at $369,000 after buying an additional 1,130 shares during the period. Finally, American International Group Inc. increased its holdings in shares of Keros Therapeutics by 13.1% during the 1st quarter. American International Group Inc. now owns 12,653 shares of the company's stock worth $838,000 after buying an additional 1,465 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.